Library of Slides and Posters
 
 

Pegylated Interferon + ribavirin

Consistency of Sustained Virologic Response (SVR) Across Weight Categories: Results From the Canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) Program
S Feinman and others.

Predictability of Response: Positive and Negative Predictive Values of Rapid and Early Virologic Responses to Peginterferon alfa-2b and Ribavirin in the Treatment of Chronic Hepatitis C
F Poordad and others

Final Results of the Canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) Program. Sustained Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b + Ribavirin in a Large, Mixed, Community and Academic Observational Study
P Marotta and others.

Treatment and Outcome of Genotype 4 Chronic Hepatitis C Patients With PegInterferon alfa 2b and Ribavirin in the Clinical Setting in Germany
D. Hueppe and others.

Clinical Relevance of Rapid Virological Response (RVR) in Decompensated HCV-Related Cirrhosis Treated With Peginterferon and Ribavirin
A Iacobellis and others.

Patient Education Improves Adherence to Peginterferon alfa-2b and Ribavirin in Chronic Genotype 2 or 3 Hepatitis C Virus Infection: A Prospective, Real-Life Study (CHEOBS Study)
P Cacoub and others.

Rapid Virological Response at Week 4 Is the Best Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: A Multivariate Analysis
M Martinot-Peignoux and others.

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction in Fibrosis and Inflammatory Scores in Chronic Hepatitis C Nonresponder Patients With Fibrosis or Cirrhosis
S. Kaiser and others.